Filing Flows

Filing Flows › Health Care › Siga Technologies (SIGA)

Siga Technologies (SIGA) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Siga Technologies (SIGA) Q2 2026 earnings results →

Q2 2026 Revenue down 50% year over year to $41.0M · 30¢ of every $1 of revenue kept as net profit · operating margin 33.9%

Siga Technologies made $41.0M in Q2 2026 (-50% Y/Y): Product Sales and Supportive Services $37.9M, Research and Development $3.1M. Operating margin 33.9%, net earnings $12.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.

Revenue$41.0M
Year over year-50%
Operating margin33.9%
Net earnings$12.5M
Operating cash flow$15.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $41.0M in Q2 2026, down 49% year over year and up 557% from the previous quarter. Product Sales and Supportive Services was the largest line at 92% of revenue. Product Sales and Supportive Services lost $41.3M year over year (down 52%), 103% of the total change.

Operating profit was $13.9M, a 33.9% margin (down 22.4 points year over year). Total costs fell 24% while revenue fell 49%. Net earnings were $12.5M, down 65% year over year. The effective tax rate was 16.1%.

Operating cash flow was $15.2M (down 76% year over year), 122% of net earnings. Non-cash charges added back $152K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $1.3M.

Quarterly history

Siga Technologies revenue by quarterSiga Technologies revenue by quarter$81.5MQ4 2024$7.0MQ1 2025$81.1MQ2 2025$2.6MQ3 2025$3.8MQ4 2025$6.2MQ1 2026$41.0MQ2 2026
Siga Technologies net earnings by quarterSiga Technologies net earnings by quarter$45.8MQ4 2024−$408KQ1 2025$35.5MQ2 2025−$6.4MQ3 2025−$5.4MQ4 2025−$3.5MQ1 2026$12.5MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 6, 2026$41.0M-50%33.9%$12.5M$15.2M
Q1 202610-QMay 7, 2026$6.2M-11%-85.2%−$3.5M−$8.7M
Q4 202510-KMar 10, 2026$3.8M-95%-250.4%−$5.4M−$16.9M
Q3 202510-QNov 6, 2025$2.6M-74%-390.2%−$6.4M−$9.8M
Q2 202510-QAug 5, 2025$81.1M+272%56.3%$35.5M$63.1M
Q1 202510-QMay 8, 2025$7.0M-72%-32.0%−$408K$7.1M
Q4 202410-KMar 11, 2025$81.5M-30%70.1%$45.8M$56.3M

Charts

Siga Technologies: revenue growth, year over year and quarter over quarterSiga Technologies: revenue growth, year over year and quarter over quarterY/YQ/Q-30%Q4 2024-72%-91%Q1 2025+272%+400%Q2 2025-74%-97%Q3 2025-95%+45%Q4 2025-11%+65%Q1 2026-50%+400%Q2 2026
Latest (Q2 2026): Y/Y -50%, Q/Q +400%.
Siga Technologies: where the cash came from (+) and went (−), TTM to Q2 2026Siga Technologies: where the cash came from (+) and went (−), TTM to Q2 2026Cash drawn (+) / kept (−)$64.9MDividends−$43.6MOperating cash flow−$20.2MTaxes on employees’ shares−$827KCapital spending−$330K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Siga Technologies: profit against cash, quarter by quarterSiga Technologies: profit against cash, quarter by quarterNet incomeOperating cash flow$1.3M−$7.4MQ3 2024$45.8M$56.3MQ4 2024−$408K$7.1MQ1 2025$35.5M$63.1MQ2 2025−$6.4M−$9.8MQ3 2025−$5.4M−$16.9MQ4 2025−$3.5M−$8.7MQ1 2026$12.5M$15.2MQ2 2026
Latest (Q2 2026): Net income $12.5M, Operating cash flow $15.2M.
Siga Technologies: diluted shares by fiscal yearSiga Technologies: diluted shares by fiscal year79MFY202076MFY202174MFY202272MFY202372MFY202472MFY2025
-9.5% since FY2020: buybacks shrank the count.
Siga Technologies in its industry: growth against margin (225 companies, SIC 2834)Siga Technologies in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMSIGA (-50%, 34%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Siga Technologies

We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government. TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration (“FDA”) approved the oral formulation of TPOXX® for the treatment of smallpox. The Company has been delivering oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") since 2013.

In its own words, from its 10-K, filed Mar 10, 2026.

Siga Technologies against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -50% against the peers' median +7%. Operating margin: 33.9% against the peers' median 30.7%.

CompanyQuarterRevenueY/YOp. margin
SIGA Siga TechnologiesQ2 2026$41.0M-50%33.9%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Siga Technologies 10-Q on SEC EDGAR · CIK 1010086 · Pharmaceutical Preparations

13F: who owns SIGA and who is buying

Largest holders of SIGA (13F)Largest holders of SIGA (13F)Vanguard Group$16.6MBlackRock$15.2MDimensional Fund Advisors LP$9.9MAltraVue Capital, LLC$8.5MVanguard Capital Management LLC$6.2MAmerican Century Companies$5.5MArrowstreet Capital, Limited Part…$5.4MGeode Capital Management, LLC$5.2MFirst Wilshire Securities Managem…$4.9MAQR Capital Management LLC$4.5M
Funds' net buying of SIGA by quarter (13F)Funds' net buying of SIGA by quarter (13F)$4.8M2024-09−$1.5M2024-12$429K2025-03$831K2025-06−$8.1M2025-09$9.1M2025-12−$7.7M2026-03$4.0M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on SIGA

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare SIGA with

中文版：Siga Technologies（SIGA）财报

Español · Français